# Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

> **NCT01083732** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 18 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** dabigatran etexilate

## Key facts

- **NCT ID:** NCT01083732
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01083732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01083732, "Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01083732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*